627-41-8Relevant articles and documents
The methoxyallene approach to oxacycles, part 2: Stereoselective synthesis of 2,3-disubstituted oxepanes
Perez, Manuel,Canoa, Pilar,Gomez, Generosa,Teijeira, Marta,Fall, Yagamare
, p. 411 - 414 (2005)
2,3-Disubstituted oxepanes 3 and 4 were stereoselectively synthesized from methoxyallene (1) and iodide 2. The trans stereochemistry of diol 3 was established by NMR studies of the bicyclic precursor 10, while the cis stereochemistry of 4 was secured by using the highly diastereoselective reducing agent L-Selectride. Georg Thieme Verlag Stuttgart.
Methoxyallene, a building block for the synthesis of seven-membered oxacycles
Fall, Yagamare,Gomez, Generosa,Fernandez, Carlos
, p. 8307 - 8308 (1999)
An efficient new approach for the synthesis of seven-membered oxacycles is described.
Design of a mesoscale continuous-flow route toward lithiated methoxyallene
Seghers, Sofie,Heugebaert, Thomas S. A.,Moens, Matthias,Sonck, Jolien,Thybaut, Joris W.,Stevens, Christian V.
, p. , 2248 (2018/10/20)
The unique nucleophilic properties of lithiated methoxyallene allow for C C bond formation with a wide variety of electro-philes, thus introducing an allenic group for further functionali-zation. This approach has yielded a tremendously broad range of (hetero)cyclic scaffolds, including precursors to active pharmaceutical ingredients. To date, however, its valorization at scale is hampered by the batch synthesis procedure, which suf- fers from serious safety issues. Hence, the attractive heat-and mass-transfer properties of flow technology were exploited to establish a mesoscale continuous-flow route toward lithiated methoxyallene. An excellent conversion of 94 % was obtained, corresponding to a methoxyallene throughput of 8.2 g h1. The process is characterized by short reaction times, mild reaction conditions and a stoichiometric use of reagents.
NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS
-
Page/Page column 57, (2015/04/22)
The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.
